World Journal of Endocrine Surgery

Register      Login

VOLUME 2 , ISSUE 2 ( May-August, 2010 ) > List of Articles

REVIEW ARTICLE

Prognostic Factors and Therapeutic Strategies of Thyroid Carcinomas Originating from Follicular Cells

Akira Miyauchi, Yasuhiro Ito

Citation Information : Miyauchi A, Ito Y. Prognostic Factors and Therapeutic Strategies of Thyroid Carcinomas Originating from Follicular Cells. World J Endoc Surg 2010; 2 (2):53-62.

DOI: 10.5005/jp-journals-10002-1023

Published Online: 01-08-2010

Copyright Statement:  Copyright © 2010; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

There are three types of thyroid carcinoma originating from follicular cells, papillary carcinoma (PTC), follicular carcinoma (FTC) and anaplastic carcinoma (ATC). PTC and FTC have generally indolent nature but ATC, which is believed to arise from PTC and FTC, are very progressive and display a dire prognosis. PTC and FTC are called differentiated carcinoma and regarded as a single group, but biological characteristics of these two types of carcinoma significantly differ. PTC frequently metastasizes to the regional lymph nodes and FTC generally metastasizes to distant organs such as the lung and bone. Most PTC can be diagnosed on preoperative imaging studies and fine needle aspiration biopsy (FNAB) and can be treated as malignancy. However, it is difficult to diagnose FTC preoperatively and most FTC are diagnosed on postoperative pathological examination. In this review, we describe prognostic factors of PTC and FTC and their therapeutic strategies. Furthermore, recent advances of treatment for ATC are also described.


PDF Share
  1. Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer. Thyroid 1995;5:25-28.
  2. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J Surg 2005;29:483-85.
  3. UICC: TNM classification of malignant tumors (6th ed). New York: Wiley-Liss, 2002.
  4. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-53.
  5. Prognostic factors of papillary and follicular thyroid cancer: Differences in an iodinereplete endemic goiter region. Endocr Relat Cancer 2004;11: 131-39.
  6. A novel classification system for patients with PTC: Addition of the new variable of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004;135:139-48.
  7. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:1050-58.
  8. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery 2009;145:100-05.
  9. Prognostic factors and therapeutic strategies for differentiated carcinoma of the thyroid. Endocrine J 2009;56:177-92.
  10. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
  11. Survival and causes of death in thyroid cancer: A population-based study of 2479 cases for Norway. Cancer Res 1991;51:1234-41.
  12. Natural history and clinical outcome of differentiated thyroid carcinoma: A retrospective analysis of 1503 patients treated at a single institution. Ann Oncol 2009;20:1728-35.
  13. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164:658-61.
  14. Thyroid cancer in Vaud, Switzerland: An update. Thyroid 2002;12:163-68.
  15. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann Surg Oncol 2006;13:1524-28.
  16. Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med 2007;32:440-44.
  17. Prognostic factors in papillary thyroid cancer: An evaluation of 601 consecutive patients. Tumour Biol 2005;26:57-64.
  18. Papillary thyroid carcinoma in Mexican patients: Clinical aspects and prognostic factors. World J Surg 1996;20:94-99.
  19. Risk factors contributing to a poor prognosis of papillary thyroid carcinoma; Validity of UICC/AJCC TNM classification and stage grouping. World J Surg 2007;31:838-48.
  20. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: Massive but not minimal extension affects the relapse-free survival. World J Surg 2006;30:780-86.
  21. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003;13:381-88.
  22. Papillary microcarcinoma of the thyroid: How should it be treated? World J Surg 2004;28:1115-21.
  23. A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nature Clin Pract Endocrinol Metab 2007;3:240-48.
  24. An observation trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010;34:28-35.
  25. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: Our treatment strategies and outcomes. World J Surg 2010. Jan 12. Epub ahead of print.
  26. Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy. World J Surg 2009. Dec 30 Epub ahead of print.
  27. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: Validity of prophylactic modified radical neck dissection. World J Surg 2007;31:2085-91.
  28. Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. World J Surg 2008;32:2494-502.
  29. Prognostic factors in papillary carcinoma of the thyroid. Cancer 1991;68:324-30.
  30. Multivariate analysis of histopathological features as prognostic factors in patients with papillary thyroid carcinoma. Br J Surg 1995;82:1092-94.
  31. Prognostic factors in differentiated thyroid carcinoma: A multivariate analysis of 234 consecutive patients. J Surg Oncol 1998;68:237-41.
  32. Prognostic variables of papillary thyroid carcinoma with local invasion. Endocrine J 1999;46:91-98.
  33. Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45. Surg Today 2006;36:12-18.
  34. Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma. World J Surg 2007;31:1196-203.
  35. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer 1999;86:842-49.
  36. Papillary thyroid carcinoma: A multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. Eur J Surg 1992; 158:583-89.
  37. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994; 18:559-67.
  38. Prognostically relevant factors in papillary thyroid cancer. Med Klin 1991;86:76-82.
  39. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 1996;3:534-38.
  40. Prognostic factors in patients with differentiated thyroid carcinoma. Eur J Surg 2000; 166:29-33.
  41. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse repalse-free survival in patients with papillary thyroid carcinoma. World J Surg 2005; 29:917-20.
  42. Prognosis of patients with papillary carcinoma having clinically apparent metastasis to the lateral compartment. Endocr J 2009;56:759-66.
  43. Distant metastasis in papillary thyroid carcnoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995;80:2041-45.
  44. Long-term results of treatment of 283 patients with lung and bone metastasis from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-67.
  45. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994;18:600-04.
  46. Differentiated thyroid carcinoma with distant metastases at presentation: Prognostic factors and outcome. Clin Endocrinol 2005;63:87-93.
  47. Papillary thyroid carcinoma with distant metastases: Survival predictors and the importance of local control. Surgery 2008;143:35-42.
  48. Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan. Endocr J 2010 Apr 6 Epub ahead of print.
  49. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high risk group of papillary and follicular carcinomas. Cancer 1983; 53:1849-55.
  50. Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans' “Wuchende Struma”. Am J Surg Pathol 1984;8:655-68.
  51. Poorly differentiated carcinoma. In: DeLeillis RA, Lloyd RV, Heitz PU, et al (Eds). Pathology and genetics of tumors of endocrine organs. IARC Press, Lyon, 2004;73-76.
  52. Poorly differentiated thyroid carcinoma: The Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007;31:1256-64.
  53. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: A clinicopathologic study of 58 patients. Canceer 2006;106: 1286-95.
  54. Poorly differentiated thyroid carcinoma: Diagnostic features and controversial issues. Endocr Pathol 2008;19:150-55.
  55. Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg 2008;32: 1535-43.
  56. Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country. World J Surg 2009 Dec 1 Epub ahead of print.
  57. Prevalence and biological behaviour of variants of papillary thyroid carcinoma: Experience at a single institute. Pathology 2008;40:617-22.
  58. Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas. Jpn J Clin Oncol 2006;36: 688-93.
  59. Follicular variant of papillary thyroid carcinoma: A clinicopathologic study of a problematic entity. Cancer 2006;107:1255-64.
  60. Warthin tumor-like variant of papillary thyroid carcinoma: A case with dedifferentiation (anaplastic change) and aggressive biological behavior. Endocr Pathol 2005;16:83-89.
  61. Clinicopathological study of the diffuse sclerosing variety of papillary cancer of the thyroid. Resentation of 4 new cases and review of literature. Eur J Surg Oncol 1994;20:7-11.
  62. Diffuse sclerosing variant of papillary thyroid carcinoma. A clinicopathologic study of 10 cases. Pathol Res Pract 1989;185:200-06.
  63. Diffuse sclerosing variant of papillary thyroid carcinoma. Am J Surg Pathol 1991;15:492-93.
  64. Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: An 18-year experience at a single institution. World J Surg 2009;33:958-62.
  65. Biological behavior and prognosis of encapsulated papillary carcinoma of he thyroid; experience of a Japanese hospital for thyroid care. World J Surg 2008;32:1789-94.
  66. Importance of lymph node metastasis in follicular thyroid cancer. World J Surg 2002;26:1017-22.
  67. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995; 118:1131-38.
  68. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1991;66:11-22.
  69. Is patient's age a prognostic factor for follicular thyroid carcinoma in the TNM classification system? Thyroid 2005;15:439-48.
  70. Follicular thyroid carcinoma. Cancer 2002;95:488-98.
  71. Risk factors in follicular thyroid carcinoma. Am J Surg Pathol 1986;10:246-55.
  72. Prognosis and prognostic factors of follicular carcinoma in Japan: Importance of postoperative pathological examination. World J Surg 2007; 31:1417-24.
  73. Hurthle cell carcinoma. Curr Treat Options Oncol 2001;2:331-35.
  74. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg 2008;195:457-62.
  75. Follicular thyroid cancer. Endocrinol Metab Clin North Am 1995;24:761-801.
  76. Hurthle cell tumor of the thyroid: Analysis of 188 cases. World J Surg 2001;25:1160-63.
  77. The treatment and prognosis of Hurthle cell follicular thyroid carcinoima compared with its non-Hurthel cell counterpart. Surgery 2005;138:1152-57.
  78. Prognostic factors in follicular carcinoma of the thyroid: A multivariate survival analysis. Eur J Surg Oncol 1999;25:599-605.
  79. Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases. Cancer 1990;66:321-30.
  80. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:1330-35.
  81. Anaplastic carcinoma of the thyroid. Am J Surg 1999;177:337-39.
  82. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 2001;25:617-22.
  83. Prognostic factors in anaplastic carcinoma. Surg Today 2004;34:394-98.
  84. Investigation of the validity of UICC stage grouping of anaplastic carcinioma of the thyroid. Asian J Surg 2009;32:47-50.
  85. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002;131:245-48.
  86. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninetysix- hour infusion. Tyroid 2000;10:587-94.
  87. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 2010;20:7-14.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.